FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
dated July 5, 2019
Commission File Number 0-51504
GENETIC TECHNOLOGIES LIMITED
(Exact Name as Specified in its Charter)
N/A
(Translation of Registrants Name)
60-66 Hanover Street
Fitzroy
Victoria 3065 Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: July 5, 2019
|
GENETIC TECHNOLOGIES LIMITED | ||
|
|
| |
|
By: |
/s/ Paul Viney | |
|
Name: |
Paul Viney | |
|
Title: |
Company Secretary | |
ASX ANNOUNCEMENT |
|
5 July 2019 |
|
Lapse of Employee Share Options
Melbourne, Australia, 5 July 2019:
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, Company), advises that 500,000 unlisted share options granted pursuant to the Companys employee option plan have lapsed. The details of these lapsed options are:
Unlisted employee option |
|
Exercise price |
|
Options lapsed |
| |
GTGAD (expiring 11 December 2021) |
|
$ |
0.010 |
|
500,000 |
|
Total |
|
|
|
500,000 |
| |
Accordingly, as at the date of this announcement, there are a total of 38,000,000 outstanding options over shares in the Company.
About Genetic Technologies Limited
Genetic Technologies is a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Companys lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visit www.brevagenplus.com and www.phenogensciences.com.
Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com
Safe Harbor Statement
Any statements in this press release that relate to the Companys expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Companys actual results may differ materially from expected results. Additional risks associated with Genetic Technologies business can be found in its periodic filings with the SEC.
FOR FURTHER INFORMATION PLEASE CONTACT
Mr Paul Viney
Company Secretary
Genetic Technologies Limited
+61438072616
Genetic Technologies Limited · Website: www.gtglabs.com · Email: info@gtglabs.com ABN 17 009 212 328
Registered Office · 60-66 Hanover Street Fitzroy Victoria 3065 Australia · Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia
Phone +61 3 8412 7000 · Fax +61 3 8412 7040
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end